Related Experiment Video
Updated: Jan 31, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
Richard J Rebello1, Christoph Oing1,2, Silke Gillessen1,3
1Translational Oncogenomics Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre, Manchester, United Kingdom.
Abstract:
Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.
Related Concept Videos
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...
What is Conservation Biology?
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Comparing the Survival Analysis of Two or More Groups
Truncation in Survival Analysis
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...

